Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myelom...
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In this multi-center, Phase-1 study (NCT03733717), we characterized the pharmacokinetics (PK) of the anti-CD38 antibody isatuximab (Isa) after IV administration (primary objective), and evaluated safety, immunogenicity, and preliminary anti-myeloma activity in Chinese patients with relapsed/refractory multiple myeloma (RRMM). Isa 20-mg/kg was admin...
Alternative Titles
Full title
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0b895c9da45f42e38c4d68e5d4bc73e9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0b895c9da45f42e38c4d68e5d4bc73e9
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-024-59186-1
